Literature DB >> 27798625

The genomic landscape of core-binding factor acute myeloid leukemias.

Zachary J Faber1, Xiang Chen2, Amanda Larson Gedman1, Kristy Boggs2, Jinjun Cheng1, Jing Ma1, Ina Radtke1, Jyh-Rong Chao1, Michael P Walsh1, Guangchun Song1, Anna K Andersson1, Jinjun Dang1, Li Dong1, Yu Liu2, Robert Huether2, Zhongling Cai1, Heather Mulder2, Gang Wu2, Michael Edmonson2, Michael Rusch2, Chunxu Qu2, Yongjin Li2, Bhavin Vadodaria2, Jianmin Wang2, Erin Hedlund2, Xueyuan Cao3, Donald Yergeau2, Joy Nakitandwe1, Stanley B Pounds3, Sheila Shurtleff1, Robert S Fulton4, Lucinda L Fulton4, John Easton2, Evan Parganas1, Ching-Hon Pui5, Jeffrey E Rubnitz5, Li Ding4, Elaine R Mardis4, Richard K Wilson4, Tanja A Gruber5, Charles G Mullighan1, Richard F Schlenk6, Peter Paschka6, Konstanze Döhner6, Hartmut Döhner6, Lars Bullinger6, Jinghui Zhang2, Jeffery M Klco1, James R Downing1.   

Abstract

Acute myeloid leukemia (AML) comprises a heterogeneous group of leukemias frequently defined by recurrent cytogenetic abnormalities, including rearrangements involving the core-binding factor (CBF) transcriptional complex. To better understand the genomic landscape of CBF-AMLs, we analyzed both pediatric (n = 87) and adult (n = 78) samples, including cases with RUNX1-RUNX1T1 (n = 85) or CBFB-MYH11 (n = 80) rearrangements, by whole-genome or whole-exome sequencing. In addition to known mutations in the Ras pathway, we identified recurrent stabilizing mutations in CCND2, suggesting a previously unappreciated cooperating pathway in CBF-AML. Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex. This detailed analysis provides insights into the pathogenesis and development of CBF-AML, while highlighting dramatic differences in the landscapes of cooperating mutations for these related AML subtypes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27798625      PMCID: PMC5508996          DOI: 10.1038/ng.3709

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  77 in total

1.  Prp43: An RNA helicase-like factor involved in spliceosome disassembly.

Authors:  J E Arenas; J N Abelson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

Authors:  Jie He; Omar Abdel-Wahab; Michelle K Nahas; Kai Wang; Raajit K Rampal; Andrew M Intlekofer; Jay Patel; Andrei Krivstov; Garrett M Frampton; Lauren E Young; Shan Zhong; Mark Bailey; Jared R White; Steven Roels; Jason Deffenbaugh; Alex Fichtenholtz; Timothy Brennan; Mark Rosenzweig; Kimberly Pelak; Kristina M Knapp; Kristina W Brennan; Amy L Donahue; Geneva Young; Lazaro Garcia; Selmira T Beckstrom; Mandy Zhao; Emily White; Vera Banning; Jamie Buell; Kiel Iwanik; Jeffrey S Ross; Deborah Morosini; Anas Younes; Alan M Hanash; Elisabeth Paietta; Kathryn Roberts; Charles Mullighan; Ahmet Dogan; Scott A Armstrong; Tariq Mughal; Jo-Anne Vergilio; Elaine Labrecque; Rachel Erlich; Christine Vietz; Roman Yelensky; Philip J Stephens; Vincent A Miller; Marcel R M van den Brink; Geoff A Otto; Doron Lipson; Ross L Levine
Journal:  Blood       Date:  2016-03-10       Impact factor: 22.113

3.  RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.

Authors:  Elli Papaemmanuil; Inmaculada Rapado; Yilong Li; Nicola E Potter; David C Wedge; Jose Tubio; Ludmil B Alexandrov; Peter Van Loo; Susanna L Cooke; John Marshall; Inigo Martincorena; Jonathan Hinton; Gunes Gundem; Frederik W van Delft; Serena Nik-Zainal; David R Jones; Manasa Ramakrishna; Ian Titley; Lucy Stebbings; Catherine Leroy; Andrew Menzies; John Gamble; Ben Robinson; Laura Mudie; Keiran Raine; Sarah O'Meara; Jon W Teague; Adam P Butler; Giovanni Cazzaniga; Andrea Biondi; Jan Zuna; Helena Kempski; Markus Muschen; Anthony M Ford; Michael R Stratton; Mel Greaves; Peter J Campbell
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 38.330

4.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27.

Authors:  C Bouchard; K Thieke; A Maier; R Saffrich; J Hanley-Hyde; W Ansorge; S Reed; P Sicinski; J Bartek; M Eilers
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

5.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Alice Marceau-Renaut; Nicolas Boissel; Arnaud Petit; Maxime Bucci; Sandrine Geffroy; Hélène Lapillonne; Aline Renneville; Christine Ragu; Martin Figeac; Karine Celli-Lebras; Catherine Lacombe; Jean-Baptiste Micol; Omar Abdel-Wahab; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

Authors:  N Boissel; H Leroy; B Brethon; N Philippe; S de Botton; A Auvrignon; E Raffoux; T Leblanc; X Thomas; O Hermine; B Quesnel; A Baruchel; G Leverger; H Dombret; C Preudhomme
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

7.  Histone demethylase UTX and chromatin remodeler BRM bind directly to CBP and modulate acetylation of histone H3 lysine 27.

Authors:  Feng Tie; Rakhee Banerjee; Patricia A Conrad; Peter C Scacheri; Peter J Harte
Journal:  Mol Cell Biol       Date:  2012-04-09       Impact factor: 4.272

8.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.

Authors:  Jennifer Edelmann; Karlheinz Holzmann; Florian Miller; Dirk Winkler; Andreas Bühler; Thorsten Zenz; Lars Bullinger; Michael W M Kühn; Andreas Gerhardinger; Johannes Bloehdorn; Ina Radtke; Xiaoping Su; Jing Ma; Stanley Pounds; Michael Hallek; Peter Lichter; Jan Korbel; Raymonde Busch; Daniel Mertens; James R Downing; Stephan Stilgenbauer; Hartmut Döhner
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

9.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Authors:  Peter Paschka; Juan Du; Richard F Schlenk; Verena I Gaidzik; Lars Bullinger; Andrea Corbacioglu; Daniela Späth; Sabine Kayser; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Claus-Henning Köhne; Gerhard Held; Marie von Lilienfeld-Toal; Heinz Kirchen; Mathias Rummel; Katharina Götze; Heinz-August Horst; Mark Ringhoffer; Michael Lübbert; Mohammed Wattad; Helmut R Salih; Andrea Kündgen; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2012-10-31       Impact factor: 22.113

10.  De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.

Authors:  Ghayda Mirzaa; David A Parry; Andrew E Fry; Kristin A Giamanco; Jeremy Schwartzentruber; Megan Vanstone; Clare V Logan; Nicola Roberts; Colin A Johnson; Shawn Singh; Stanislav S Kholmanskikh; Carissa Adams; Rebecca D Hodge; Robert F Hevner; David T Bonthron; Kees P J Braun; Laurence Faivre; Jean-Baptiste Rivière; Judith St-Onge; Karen W Gripp; Grazia Ms Mancini; Ki Pang; Elizabeth Sweeney; Hilde van Esch; Nienke Verbeek; Dagmar Wieczorek; Michelle Steinraths; Jacek Majewski; Kym M Boycot; Daniela T Pilz; M Elizabeth Ross; William B Dobyns; Eamonn G Sheridan
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  102 in total

Review 1.  Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Authors:  Shuhei Asada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2018-12-05       Impact factor: 2.490

2.  Recurrent cyclin D2 mutations in myeloid neoplasms.

Authors:  V Khanna; C A Eide; C E Tognon; J E Maxson; B Wilmot; D Bottomly; S McWeeney; D K Edwards V; B J Druker; J W Tyner
Journal:  Leukemia       Date:  2017-06-20       Impact factor: 11.528

Review 3.  Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

Authors:  Xi Quan; Jianchuan Deng
Journal:  Mol Clin Oncol       Date:  2020-05-25

Review 4.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Authors:  Stephen A Strickland; Aaron C Shaver; Michael Byrne; Robert D Daber; P Brent Ferrell; David R Head; Sanjay R Mohan; Claudio A Mosse; Tamara K Moyo; Thomas P Stricker; Cindy Vnencak-Jones; Michael R Savona; Adam C Seegmiller
Journal:  Leuk Res       Date:  2018-01-02       Impact factor: 3.156

6.  Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Authors:  N Jahn; M Agrawal; L Bullinger; D Weber; A Corbacioglu; V I Gaidzik; L Schmalbrock; F Thol; M Heuser; J Krauter; G Göhring; A Kündgen; W Fiedler; M Wattad; G Held; C-H Köhne; H-A Horst; M Lübbert; A Ganser; R F Schlenk; H Döhner; K Döhner; P Paschka
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

7.  Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Authors:  Nikolaus Jahn; Tobias Terzer; Eric Sträng; Anna Dolnik; Sibylle Cocciardi; Ekaterina Panina; Andrea Corbacioglu; Julia Herzig; Daniela Weber; Anika Schrade; Katharina Götze; Thomas Schröder; Michael Lübbert; Dominique Wellnitz; Elisabeth Koller; Richard F Schlenk; Verena I Gaidzik; Peter Paschka; Frank G Rücker; Michael Heuser; Felicitas Thol; Arnold Ganser; Axel Benner; Hartmut Döhner; Lars Bullinger; Konstanze Döhner
Journal:  Blood Adv       Date:  2020-12-22

8.  ZBTB7A governs estrogen receptor alpha expression in breast cancer.

Authors:  Mary Ellen Molloy; Monika Lewinska; Amanda K Williamson; Thanh Thao Nguyen; Gamze Kuser-Abali; Lu Gong; Jiawei Yan; John B Little; Pier Paolo Pandolfi; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2018-08-01       Impact factor: 6.216

Review 9.  Cohesin Mutations in Myeloid Malignancies.

Authors:  Joseph B Fisher; Maureen McNulty; Michael J Burke; John D Crispino; Sridhar Rao
Journal:  Trends Cancer       Date:  2017-04

10.  Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome.

Authors:  Lu Jiang; Xue-Ping Li; Yu-Ting Dai; Bing Chen; Xiang-Qin Weng; Shu-Min Xiong; Min Zhang; Jin-Yan Huang; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.